Hypertension become the main problem for Indonesian society with 32,2% of prevalence. There are many recommendations of treatment theraphy. The combination usage of conventional anti-hypertension is one of the recommendations from JNC VIII. The Ministry of Health through B2P2TOOT is successfully produce anti-hypertension jamu saintifik that intented for complementary theraphy. Today, the effectiveness of reaching blood pressure target is still being a problem for anti-hypertension conventional theraphy as well jamu saintifik (certified jamu). Moreover, the big cost for each theraphy is still being a consideration for the medical patient in determining the kind of theraphy they will choosen. Based on the problem mentioned before, there will be a research about the cost effectiveness analysis between anti-hypertension jamu saintifik and combination of conventional anti-hypertension. The analytic observational was used as the research design and Incremental Cost Effectiveness Ratio (ICER) method was used as the data analysis, and interpreted by Cost Effectiveness Plane (CEP). The cost data is taken using provider perspektive as a health service provider. There were 56 medical patients as the respondent that consist of 30 combination theraphy conventional anti-hypertension medical patients in Puskesmas Kalibakung and 26 anti-hypertension jamu saintifik theraphy medical patients in Wisata Kesehatan Jamu Kalibakung. The precentage of success effectiveness of combination theraphy conventional anti-hypertension reached 40%, while the precentage of success effectiveness of anti-hypertension jamu saintifik theraphy reached 53,8%. The average of total cost per medical patient for combination theraphy conventional anti-hypertension was Rp 133.196 and Rp 102.138 for anti-hypertension jamu saintifik theraphy. ICER was used for analyze the data and gain the ICER value Rp -2.257/medical patient as the result. The interpretation of ICER value by CEP concluded that anti-hypertension jamu saintifik theraphy is more cost effective than combination theraphy conventional anti-hypertension because the ICER value is in the SouthEast area.